MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1371/journal.pone.0081564

Медицинская библиотека · PloS one · 2013

Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment.

Nyendak Melissa R, Park Byung, Null Megan D, Baseke Joy, Swarbrick Gwendolyn, Mayanja-Kizza Harriet, Nsereko Mary, Johnson Denise F, Gitta Phineas, Okwera Alphonse, Goldberg Stefan, Bozeman Lorna, Johnson John L, Boom W Henry, Lewinsohn Deborah A, Lewinsohn David M, Tuberculosis Research Unit and the Tuberculosis Trials Consortium

Клиническое исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

RATIONALE: Biomarkers associated with response to therapy in tuberculosis could have broad clinical utility. We postulated that the frequency of Mycobacterium tuberculosis (Mtb) specific CD8(+) T cells, by virtue of detecting intracellular infection, could be a surrogate marker of response to therapy and would decrease during effective antituberculosis treatment.

OBJECTIVES

We sought to determine the relationship of Mtb specific CD4(+) T cells and CD8(+) T cells with duration of antituberculosis treatment.

MATERIALS AND

METHODS

We performed a prospective cohort study, enrolling between June 2008 and August 2010, of HIV-uninfected Ugandan adults (n = 50) with acid-fast bacillus smear-positive, culture confirmed pulmonary TB at the onset of antituberculosis treatment and the Mtb specific CD4(+) and CD8(+) T cell responses to ESAT-6 and CFP-10 were measured by IFN-γ ELISPOT at enrollment, week 8 and 24.

RESULTS

There was a significant difference in the Mtb specific CD8(+) T response, but not the CD4(+) T cell response, over 24 weeks of antituberculosis treatment (p<0.0001), with an early difference observed at 8 weeks of therapy (p = 0.023). At 24 weeks, the estimated Mtb specific CD8(+) T cell response decreased by 58%. In contrast, there was no significant difference in the Mtb specific CD4(+) T cell during the treatment. The Mtb specific CD4(+) T cell response, but not the CD8(+) response, was negatively impacted by the body mass index.

CONCLUSIONS

Our data provide evidence that the Mtb specific CD8(+) T cell response declines with antituberculosis treatment and could be a surrogate marker of response to therapy. Additional research is needed to determine if the Mtb specific CD8(+) T cell response can detect early treatment failure, relapse, or to predict disease progression.

Для цитирования: Nyendak Melissa R, Park Byung, Null Megan D, Baseke Joy, Swarbrick Gwendolyn, Mayanja-Kizza Harriet, Nsereko Mary, Johnson Denise F, Gitta Phineas, Okwera Alphonse, Goldberg Stefan, Bozeman Lorna, Johnson John L, Boom W Henry, Lewinsohn Deborah A, Lewinsohn David M, Tuberculosis Research Unit and the Tuberculosis Trials Consortium. Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment.. PloS one. 2013. DOI: 10.1371/journal.pone.0081564.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.